Bioactive Salen-type Schiff Base Transition Metal Complexes as Possible Anticancer Agents

Document Type : Research article

Authors

1 Department of Inorganic Chemistry, Faculty of Chemistry, Semnan University, Semnan, Iran.

2 Department of Medical Nanotechnology, Faculty of Advanced Technology in Medicine, Iran University of Medical Sciences, Tehran, Iran.

3 Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Although metal-based anticancer drugs have been recognized as the most effective agents over the organic compounds, non-selectivity and high toxic effects have limited their applications in a way that only three Pt-analogues have progressed into clinical use. These problems have spurred chemists to develop different strategies based on alternative targets. This work focuses on predicting potency and mode of interactions of a series of salen type Schiff base transition metal complexes derived from meso-1,2-diphenyl-1,2-ethylenediamine, over some proteins (HDAC7, HDAC2, CatB, B-RAF kinase, TopII, RNR, TS, and rHA) using computational docking method, to be later considered as possible anticancer agents. The obtained results showed that all complexes exhibited higher affinity for HDAC7 than the other targets. Moreover, the bromo-derivatives of the copper compounds were more active on HDAC7 than the other derivatives. Such bromo compounds showed considerable interactions with Kinase, RNR, TS, and CatB. Contrary to Histone deacetylase (HAD)C7; HDAC2 was predicted to be relatively poor target. As expected, formation of the hydrophobic interactions between the metal complexes and the protein targets were essential for activity of the metal compounds. This study provides some more information for further optimizations and development of new metallodrugs as enzyme inhibitors for potential therapeutic agents.

Keywords

Main Subjects


(1)
(2)
(3)
Rosenberg B. Platinum Complexes for the Treatment
of Cancer. Interdiscip. Sci. Rev. (1978) 3: 134–47.
Leite SM, Lima LM, Gama S, Mendes F, Orio M,
Bento I, Paulo A, Delgado R and Iranzo O. Copper(II)
complexes of phenanthroline and histidine containing
ligands: synthesis, characterization and evaluation of
their DNA cleavage and cytotoxic activity. Inorg.
Chem. (2016) 55: 11801–14.
Mjos MD and Orvig C. Metallodrugs in medicinal
inorganic chemistry. Chem. Rev. (2014) 114: 4540−63.
Schiff Base Complexes as Anticancer Agents
2065
Gasser G, Ott I and Metzler-Nolte N. Organometallic
anticancer compounds. J. Med. Chem. (2011) 54:
3–25.
Manikandan R and Viswnathamurthi P. Coordination
behavior of ligand based on NNS and NNO donors
with ruthenium (III) complexes and their catalytic and
DNA interaction studies. Spectrochim. Acta A Mol.
Biomol. Spectrosc. (2012) 97: 864-70.
Feng L, Geisselbrecht Y, Blanck S, Wilbuer A, AtillaGokcumen GE, Filippakopoulos G, Celik MA, Harms
K, Maksimoska J, Marmorstein R, Frenking G, Knapp
S, Essen LO and Meggers E. Structurally sophisticated
octahedral metal complexes as highly selective protein
kinase inhibitors. J. Am. Chem. Soc. (2011) 133:
5976–86.
Yang M, Pickard AJ, Qiao X, Gueble MJ, Day CS,
Kucera GL and Bierbach U. Synthesis, reactivity, and
biological activity of gold(I) complexes modified with
thiourea-functionalized tyrosine kinase inhibitors.
Inorg. Chem. (2015) 54: 3316−24.
Spencer J, Amin J, Wang MH, Packham G, Alwi SS,
Tizzard GJ, Coles SJ, Paranal RM, Bradner JE and
Heightman TD. Synthesis and biological evaluation
of JAHAs: ferrocene-based histone deacetylase
inhibitors. ACS Med. Chem. Lett. (2011) 2: 358-36.
Kasparkova J, Kostrhunova H, Novakova O,
Křikavová R, Vančo J, Trávníček Z and Brabec V.
A photoactivatable platinum(IV) complex targeting
genomic DNA and histone deacetylases. Angew.
Chem. Int. Ed. Engl. (2015) 54: 14478-82.
Ruiz J, Vicente C, Haro C and Bautista D. Novel bisC,N-cyclometalated iridium(III) thiosemicarbazide
antitumor complexes: interactions with human serum
albumin and DNA, and inhibition of cathepsin B.
Inorg. Chem. (2013) 52: 974-82.
Rojas S, Carmona FJ, Barea E and Maldonado CR.
Inorganic mesoporous silicas as vehicles of two novel
anthracene-based ruthenium metalloarenes. J. Inorg.
Biochem. (2017) 166: 87–93.
Fillipe V, Rochaa FV, Barraa CV, Garridoc SS,
Manented FA, Carlosd IZ, Ellenae J, Fuentesf AS,
Gautierg A, Morelh L, Mauroa AE and Netto AV.
Cationic Pd(II) complexes acting as topoisomerase
II inhibitors: synthesis, characterization, DNA
interaction and cytotoxicity. J. Inorg. Biochem. (2016)
159: 165–8.
Sandhausa S, Taylorb R, Edwardsb T, Huddlestonb A,
Wootenb Y, Venkatramanc R, Weberd RT, GonzálezSarríase A, Martinf PM, Caglef P, Tse-Dinha YC,
Beebeh S, Seerame N and Holderi AA. A novel
copper(II) complex identified as a potent drug against
colorectal and breast cancer cells and as a poison
inhibitor for human topoisomerase IIα. Inorg. Chem.
Commun. (2016) 64: 45–9.
Zaltariov MF, Hammerstad M, Arabshahi HJ,
Jovanović K, Richter KW, Cazacu M, Shova S,
Balan M, Andersen NH, RadulovićS, Reynisson JH,
Andersson KK and Arion VB. New Iminodiacetate−
thiosemicarbazone hybrids and their copper(II)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
complexes are potential Ribonucleotide reductase R2
inhibitors with high antiproliferative activity. Inorg.
Chem. (2017) 56: 3532-49.
Pelà M, Saxena P, Luciani R, Santucci M, Ferrari
S, Marverti G, Marraccini C, Martello A, Pirondi S,
Genovese F, Salvadori S, D’Arca D, Ponterini G,
Costi MP and Guerrini R. Optimization of peptides
that target human thymidylate synthase inhibit on
ovarian cancer cell growth. J. Med. Chem. (2014) 57:
1355–67.
Tavares TT, Azevedo GC, Garcia A, Carpanez AG,
Lewer PM, Paschoal D, Müller BL, Dos Santos HF,
Matos RC, Silva H, Grazul RM and Soares Fontes
AP. Gold(I) complexes with aryl-thiosemicarbazones:
molecular modeling, synthesis, cytotoxicity and TrxR
inhibition. Polyhedron (2017) 132: 95–104.
Damercheli M, Dayyani D, Behzad M, Mehravi B and
Shafiee Ardestani M. New Salen-type manganese(III)
Schiff base complexes derived from meso-1,2-
diphenyl-1,2-ethylenediamine: in-vitro anticancer
activity, mechanism of action, and molecular docking
studies. J. Coord. Chem. (2015) 68: 1500-15.
Behzad M, Seifikar Ghomi L, Damercheli M, Mehravi
B, Shafiee Ardestani M, Jahromi HS and Abbasi Z.
Crystal structures and in-vitro anticancer studies on
new unsymmetrical copper(II) Schiff base complexes
derived from meso-1,2-diphenyl-1,2-ethylenediamine:
a comparison with related symmetrical ones. J. Coord.
Chem. (2016) 69: 2469-81.
Micelli D and Rastelli G. Histone deacetylases:
structural determinants of inhibitor selectivity. Drug
Discov. Today (2015) 20: 718-35.
Aggarwal N and Sloane BF. Cathepsin B: multiple
roles in cancer. Proteomics Clin. Appl. (2014) 8: 427-
37.
Xie P, Streu C, Qin J, Bregman H, Pagano N, Meggers
E and Marmorstein R. The crystal structure of BRAF
in complex with an organoruthenium inhibitor reveals
a mechanism for inhibition of an active form of BRAF
kinase. Biochem. (2009) 48: 5187-98.
Peng-Hui L, Ping Z, Shuo-Bin C, Pei-Fen Y, YanWen M, Jia-Heng T, Tian-Miao O, Shi-Liang H,
Ding L, Lian-Quan G and Zhi-Shu H. Synthesis
and mechanism studies of 1,3-benzoazolyl substituted
pyrrolo[2,3-b]pyrazine derivatives as non-intercalative
topoisomerase II catalytic inhibitors. J. Med. Chem.
(2016) 59: 238–52.
Hu W, Luo Q, Ma X, Wu K, Liu J, Chen Y, Xiong
S, Wang J, Sadler PJ and Wang F. Arene control
over thiolate to sulfinate oxidation in albumin by
organometallic ruthenium anticancer complexes.
Chem. Eur. J. (2009) 15: 6586-94.
Farrokhnia M and Karim Mahnam K. Molecular
dynamics and docking investigations of several
zoanthamine- type marine alkaloids as matrix
metaloproteinase-1 inhibitors. Iran. J. Pharm. Res.
(2017) 16: 173-86.
Pravina N, Devarajib V and Ramana N. Targeting
protein kinase and DNA molecules by diimine–
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
 Damercheli M et al. / IJPR (2019), 18 (4): 2055-2066
2066
cryptic deacetylase activity. J. Biol. Chem. (2008) 283:
11355-63.
Leonidova A, Mari C, Aebersold C and Gasser G.
Selective Photorelease of an organometallic-containing
enzyme inhibitor. Organometallics (2016) 35: 851-4.
Cross JM, Blower TR, Gallagher N, Gill JH, Rockley
KL and Walton JW. Anticancer RuII and RhIII pianostool complexes that are histone deacetylase inhibitors.
ChemPlusChem (2016) 81: 1-6.